Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11–12
HOS-138181 · Präparat HOS-098156
11
System organ class Adverse reaction Frequency
Immune system disorders Hypersensitivity Common
+
Anaphylactic reaction Rare
+
Anaphylactic shock Rare
Metabolism and nutrition Weight decreased/Weight loss Very common
disorders Anorexia Very common
Tumour lysis syndrome Not known
Hyperkalaemia Not known
Psychiatric disorders Insomnia Very common
Anxiety Common
Depression Common
1
Nervous system disorders Tremor Very common
Dizziness Very common
Headache Very common
Paraesthesia Very common
Dysgeusia Very common
Peripheral neuropathy Common
Hypertonia Common
Somnolence Common
Eye disorders Conjunctivitis Very common
Lacrimation increased Very common
Dry eye Common
Papilloedema Not known
Retinal haemorrhage Not known
Ear and labyrinth disorders Deafness Uncommon
1
Cardiac disorders Blood pressure decreased Very common
1
Blood pressure increased Very common
1
Heart beat irregular Very common
1
Cardiac flutter Very common
Ejection fraction decreased* Very common
+
Cardiac failure (congestive) Common
+1
Supraventricular Common
tachyarrhythmia
Cardiomyopathy Common
1
Palpitation Common
Pericardial effusion Uncommon
Cardiogenic shock Not known
Gallop rhythm present Not known
Vascular disorders Hot flush Very common
+1
Hypotension Common
Vasodilatation Common
+
Respiratory, thoracic and Dyspnoea Very common
mediastinal disorders Cough Very common
Epistaxis Very common
Rhinorrhoea Very common
+
Pneumonia Common
Asthma Common
Lung disorder Common
+
Pleural effusion Common
+1
Wheezing Uncommon
Pneumonitis Uncommon
+
Pulmonary fibrosis Not known
+
Respiratory distress Not known
+
Respiratory failure Not known
+
Lung infiltration Not known
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 5bebb75cc7cca02b628e4f5b752c6a011a7f8c7bbe12a59d288d21adf420c2a4 · Zeichen 3192–7769 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12–13
HOS-138182 · Präparat HOS-098156
12
System organ class Adverse reaction Frequency
+
Acute pulmonary oedema Not known
+
Acute respiratory distress Not known
syndrome
+
Bronchospasm Not known
+
Hypoxia Not known
+
Oxygen saturation decreased Not known
Laryngeal oedema Not known
Orthopnoea Not known
Pulmonary oedema Not known
Interstitial lung disease Not known
Gastrointestinal disorders Diarrhoea Very common
Vomiting Very common
Nausea Very common
1
Lip swelling Very common
Abdominal pain Very common
Dyspepsia Very common
Constipation Very common
Stomatitis Very common
Haemorrhoids Common
Dry mouth Common
Hepatobiliary disorders Hepatocellular injury Common
Hepatitis Common
Liver tenderness Common
Jaundice Rare
Skin and subcutaneous tissue Erythema Very common
disorders Rash Very common
1
Swelling face Very common
Alopecia Very common
Nail disorder Very common
Palmar-plantar Very common
erythrodysaesthesia syndrome
Acne Common
Dry skin Common
Ecchymosis Common
Hyperhydrosis Common
Maculopapular rash Common
Pruritus Common
Onychoclasis Common
Dermatitis Common
Urticaria Uncommon
Angioedema Not known
Musculoskeletal and connective Arthralgia Very common
tissue disorders 1
Muscle tightness Very common
Myalgia Very common
Arthritis Common
Back pain Common
Bone pain Common
Muscle spasms Common
Neck Pain Common
Pain in extremity Common
Renal and urinary disorders Renal disorder Common
Glomerulonephritis membranous Not known
Glomerulonephropathy Not known
Renal failure Not known
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 0e4f611630e7224d5b4a377afacd89c9cfe2304113367091b55148a597d137b9 · Zeichen 7812–12142 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13–14
HOS-138183 · Präparat HOS-098156
13
System organ class Adverse reaction Frequency
Pregnancy, puerperium and Oligohydramnios Not known
perinatal conditions Renal hypoplasia Not known
Pulmonary hypoplasia Not known
Reproductive system and breast Breast inflammation/mastitis Common
disorders
General disorders and Asthenia Very common
administration site conditions Chest pain Very common
Chills Very common
Fatigue Very common
Influenza-like symptoms Very common
Infusion-related reaction Very common
Pain Very common
Pyrexia Very common
Mucosal inflammation Very common
Peripheral oedema Very common
Malaise Common
Oedema Common
Injury, poisoning and procedural Contusion Common
complications
+ Denotes adverse reactions that have been reported in association with a fatal outcome.
1 Denotes adverse reactions that are reported largely in association with infusion-related reactions. Specific
percentages for these are not available.
* Observed with combination therapy following anthracyclines and combined with taxanes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 47ede56233bfd017f42280f58a71aa77b91eb69270c7d4706315773f34a651dd · Zeichen 12187–14245 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-138184 · Präparat HOS-098156
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 14247–14288 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-138185 · Präparat HOS-098156
Cardiac dysfunction
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 82d0fd2187dd323ce98afcc35c14ec89281c4b5a3b13d80496c1709fa818d444 · Zeichen 14290–14309 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-138186 · Präparat HOS-098156
Congestive heart failure (NYHA class II – IV) is a common adverse reaction associated with the use
of trastuzumab and has been associated with a fatal outcome (see section 4.4). Signs and symptoms of
cardiac dysfunction such as dyspnoea, orthopnoea, increased cough, pulmonary oedema, S3 gallop, or
reduced ventricular ejection fraction, have been observed in patients treated with trastuzumab (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage fb36424c9c1dd016430f7b09bf21aa15c051df6d8aef72be0f4e90ec5c0f695e · Zeichen 14311–14723 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-138187 · Präparat HOS-098156
In 3 pivotal clinical studies of adjuvant trastuzumab given in combination with chemotherapy, the
incidence of grade 3/4 cardiac dysfunction (specifically symptomatic congestive heart failure) was
similar in patients who were administered chemotherapy alone (i.e. did not receive trastuzumab) and
in patients who were administered trastuzumab sequentially to a taxane (0.3-0.4%). The rate was
highest in patients who were administered trastuzumab concurrently with a taxane (2.0%). In the
neoadjuvant setting, the experience of concurrent administration of trastuzumab and low-dose
anthracycline regimen is limited (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 006e9e6dbdff543376fa294776844edfbad4725fff2a33bd721dc46289d1f2aa · Zeichen 14725–15358 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-138188 · Präparat HOS-098156
When trastuzumab was administered after completion of adjuvant chemotherapy NYHA class III-IV
heart failure was observed in 0.6% of patients in the one-year arm after a median follow-up of
12 months. In study BO16348, after a median follow-up of 8 years the incidence of severe CHF
(NYHA class III & IV) in the trastuzumab 1 year treatment arm was 0.8%, and the rate of mild
symptomatic and asymptomatic left ventricular dysfunction was 4.6%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage ac7ba96e892d282b777ceff897b54308393dc62b915e27240b575bd00a390e10 · Zeichen 15360–15802 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-138189 · Präparat HOS-098156
Reversibility of severe CHF (defined as a sequence of at least two consecutive LVEF values ≥ 50%
after the event) was evident for 71.4% of trastuzumab-treated patients. Reversibility of mild
symptomatic and asymptomatic left ventricular dysfunction was demonstrated for 79.5% of patients.
Approximately 17% of cardiac dysfunction related events occurred after completion of trastuzumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 768f5d38b731db16ee029bdfc9c45c56fa2619e1c1f43ae2ebe70f343701635e · Zeichen 15804–16190 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-138190 · Präparat HOS-098156
In the pivotal metastatic studies of intravenous trastuzumab, the incidence of cardiac dysfunction
varied between 9% and 12% when it was combined with paclitaxel compared with 1%-4% for
paclitaxel alone. For monotherapy, the rate was 6%-9%. The highest rate of cardiac dysfunction was
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage bf89a1491edb901fea78639b2887cd38adfa8c60f36afa1c20789609d1002435 · Zeichen 16192–16476 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14–15
HOS-138191 · Präparat HOS-098156
14
seen in patients receiving trastuzumab concurrently with anthracycline/cyclophosphamide (27%), and
was significantly higher than for anthracycline/cyclophosphamide alone (7%-10%). In a subsequent
study with prospective monitoring of cardiac function, the incidence of symptomatic CHF was 2.2% in
patients receiving trastuzumab and docetaxel, compared with 0% in patients receiving docetaxel alone.
Most of the patients (79%) who developed cardiac dysfunction in these studies experienced an
improvement after receiving standard treatment for CHF.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 8308166df6a9b2f435626af7c37664f4d044ce8cf9133f56667510ae8850e25b · Zeichen 16534–17084 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138192 · Präparat HOS-098156
Infusion reactions, allergic-like reactions and hypersensitivity
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 440b11089212cd61bbf6a0969af02756d79fb5ea6b185c5192c28459eb99ff51 · Zeichen 17086–17150 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138193 · Präparat HOS-098156
It is estimated that approximately 40% of patients who are treated with trastuzumab will experience
some form of infusion-related reaction. However, the majority of infusion-related reactions are mild to
moderate in intensity (NCI-CTC grading system) and tend to occur earlier in treatment, i.e. during
infusions one, two and three and lessen in frequency in subsequent infusions. Reactions include chills,
fever, dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation,
respiratory distress, rash, nausea, vomiting and headache (see section 4.4). The rate of infusion-related
reactions of all grades varied between studies depending on the indication, the data collection
methodology, and whether trastuzumab was given concurrently with chemotherapy or as
monotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 866c55e97ee57652cdeb4d5536fca0217d54d121a8718bcabfc09b5dd8b8521f · Zeichen 17152–17951 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138194 · Präparat HOS-098156
Severe anaphylactic reactions requiring immediate additional intervention can occur usually during
either the first or second infusion of trastuzumab (see section 4.4) and have been associated with a
fatal outcome. Anaphylactoid reactions have been observed in isolated cases.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 209c2b3c2e9b995d9b92c1bed4838be7ce48b957de142f98c5fb0aef6c726804 · Zeichen 17953–18229 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138195 · Präparat HOS-098156
Haematotoxicity
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage c92a836217b518ff3ee8b7281611922b449b8ef27012fbb89888ae8d098537f8 · Zeichen 18231–18246 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138196 · Präparat HOS-098156
Febrile neutropenia, leukopenia, anaemia, thrombocytopenia and neutropenia occurred very
commonly. The frequency of occurrence of hypoprothrombinaemia is not known. The risk of
neutropenia may be slightly increased when trastuzumab is administered with docetaxel following
anthracycline therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 6040d310db699c1d27427878021c8ab5bc06d1be230968a82fd9b0b64554ac75 · Zeichen 18248–18543 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138197 · Präparat HOS-098156
Pulmonary events
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage b061db90bf5f7b19f54b628119f12ec7fe0c59955793078bdd8f07df7eb163da · Zeichen 18545–18561 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138198 · Präparat HOS-098156
Severe pulmonary adverse reactions occur in association with the use of trastuzumab and have been
associated with a fatal outcome. These include, but are not limited to, pulmonary infiltrates, acute
respiratory distress syndrome, pneumonia, pneumonitis, pleural effusion, respiratory distress, acute
pulmonary oedema and respiratory insufficiency (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage d41e59764dbf150ae8499f0b7f7323815497b25f13c97653ef7010fe4390183b · Zeichen 18563–18928 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138199 · Präparat HOS-098156
Details of risk minimisation measures that are consistent with the EU Risk Management Plan are
presented in (see section 4.4) warnings and precautions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage 7a9840039c80ff11d17c81b629cec90dab419ae719c7aff33ad08bb9f55ae378 · Zeichen 18930–19081 im Abschnitt
Nebenwirkungen · Kanjinti
KANJINTI 150 mg powder for concentrate for solution for infusion KANJINTI 420 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-138200 · Präparat HOS-098156
Immunogenicity
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T11:54:00Z · SHA-256 64f7023b8ef470359816997a176374c724377705a011d7a85e82ff4bfbdf5d30 · Passage ae77290613846aafc55236a48c7f91da474683d42c7b59d61e17700b2c3af141 · Zeichen 19083–19097 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.